Lack of Pharmacokinetic Drug Interaction between Tenofovir Disoproxil Fumarate and Nelfinavir Mesylate-Reference-Cited by-同舟云学术

Lack of Pharmacokinetic Drug Interaction between Tenofovir Disoproxil Fumarate and Nelfinavir Mesylate

Published:2005-10 Issue:10 Volume:49 Page:4386-4389
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Boffito Marta¹,Pozniak Anton¹,Kearney Brian P.²,Higgs Christopher¹,Mathias Anita²,Zhong Lijie²,Shah Jaymin²

Affiliation:

1. PK Research, Chelsea and Westminster Hospital, London, United Kingdom

2. Gilead Sciences, Inc., Foster City, California

Abstract

ABSTRACT A study explored the pharmacokinetics of tenofovir (300 mg administered once daily) and nelfinavir (1,250 mg twice daily) when coadministered in 29 healthy volunteers. Tenofovir, nelfinavir, and M8 pharmacokinetics was unaltered when tenofovir and nelfinavir were coadministered, and tenofovir administration did not affect the M8/nelfinavir area under the concentration-versus-time curve over the dosing interval (AUC tau ) ratio. No interaction between tenofovir and nelfinavir was observed.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.49.10.4386-4389.2005

Reference14 articles.

1. Transendothelial migration of leukocytes carrying infectious HIV-1: an indicator of adverse prognosis

2. Tenofovir Diphosphate Is a Poor Substrate and a Weak Inhibitor of Rat DNA Polymerases α, δ, and ε*

3. Boffito, M., D. Back, M. Stainsby-Tron, A. Hill, G. Di Perri, G. Moyle, M. Nelson, J. Tomkins, B. Gazzard, and A. Pozniak. 2005. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir disoproxil fumarate in HIV-1-infected subjects. Br. J. Clin. Pharmacol.59:38-42.

4. Bristol Meyer Squibb Company. 2004. Reyataz [atazanavir]: summary of product characteristics. Bristol Meyer Squibb Company Princeton N.J.

5. Gallant, J. E., S. Staszewski, A. L. Pozniak, E. DeJesus, J. M. Suleiman, M. D. Miller, D. F. Coakley, B. Lu, J. J. Toole, A. K. Cheng, and the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA292:191-201.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Para‐aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research;British Journal of Clinical Pharmacology;2021-10-21

2. Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate;Antimicrobial Agents and Chemotherapy;2021-02-17

3. Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate;International Journal of Infectious Diseases;2020-08

4. Personalized Herbal Medicine? A Roadmap for Convergence of Herbal and Precision Medicine Biomarker Innovations;OMICS: A Journal of Integrative Biology;2018-06

5. The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects;Clinical Pharmacology: Advances and Applications;2017-02